Respironics
This article was originally published in The Gray Sheet
Executive Summary
Appoints board member James Liken president and CEO to succeed Dennis Meteny. The move is part of the firm's previously announced restructuring effort prompted by slowing sales growth (1"The Gray Sheet" July 12, In Brief)
You may also be interested in...
Respironics
Fourth quarter (ended June 30) results will be "lower than current analysts' expectations," the Pittsburgh firm announces July 6. Sales and earnings are projected at $90 mil. and $0.18-per-share, respectively, versus $85 mil. and $0.17 for last year's fourth quarter. Factors slowing sales growth include the Health Care Financing Administration's "challenge to coverage for our non-invasive ventilation product line," which has been "a major distraction," and "significantly slowed our customers' acceptance of this truly innovative therapy," Respironics explains (1"The Gray Sheet" July 5, p. 13). The firm plans to consolidate manufacturing, cut its workforce by 10%, divest or discontinue certain product lines and streamline operations. Specific details will be worked out by August, Respironics says. The firm plans a related, one-time, pre-tax charge of $30 mil
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.